ProtocolOpen accessMedicine· cited by 80

Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma

Eric Lim; Liz Darlison; John Edwards; Daisy Elliott; Dean A. Fennell; Sanjay Popat; Robert C. Rintoul; David Waller · 2020 · BMJ Open

WASTE classifies this as Protocol · AI classification, approximate

A protocol that failed or needed troubleshooting — useful to read before you run the same steps.

Abstract

INTRODUCTION: Mesothelioma remains a lethal cancer. To date, systemic therapy with pemetrexed and a platinum drug remains the only licensed standard of care. As the median survival for patients with mesothelioma is 12.1 months, surgery is an important consideration to improve survival and/or quality of life. Currently, only two surgical trials have been performed which found that neither extensive (extra-pleural pneumonectomy) or limited (partial pleurectomy) surgery improved survival (although there was some evidence of improved quality of life). Therefore, clinicians are now looking to evalu

Abstract by Eric Lim; Liz Darlison; John Edwards; Daisy Elliott; Dean A. Fennell; Sanjay Popat; Robert C. Rintoul; David Waller, BMJ Open (2020) — licensed CC BY 4.0.

Read the full paper (open access)